– UK, Oxford – e-therapeutics plc (LON: ETX) today announced concurrently with the decision to split the role of Executive Chairman and Chief Executive, Independent Director Professor Trevor Jones will assume the role of Independent Non-Executive Chairman alongside Ali Mortazavi who will continue in his role as CEO, with immediate effect.
Ali Mortazavi, CEO, said: “I am very pleased that Trevor has agreed to become the Non-Executive Chairman of e-therapeutics. Having served as a Non-Executive Director for many years, Trevor has an in-depth knowledge of the Company and I am very much looking forward to working more closely with him.
“Trevor has had a distinguished career at the helm of leading pharmaceutical and governmental organizations during which he has made major contributions to human health and business. His breadth of experience in all aspects of the biopharma industry will be invaluable to us as we strive to achieve our long-term ambitions in drug development.”
About Trevor Jones
Trevor has over 40 years’ experience in the pharmaceutical and biotechnology industries as well as in academia. He has held significant roles including Director of Allergan Inc. from 2005 to 2015 and R&D Director of The Wellcome Foundation from 1987 to 1994, where he was responsible for the development of AZT, Zovirax, Lamictal, and Malarone. He is Visiting Professor at King’s College, London, and holds honorary degrees and Gold Medals from seven universities.
Professor Trevor Jones commented: “I am delighted with my appointment. e-therapeutics has a world-class team of scientists who are discovering entirely novel therapeutics using their unique approach to network pharmacology. The appointment last year of Ali Mortazavi has led to a step-change in the Company’s performance and we are in a strong position to continue our successful internal programs and partnerships with major pharmaceutical and biotech companies.”
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a powerful computer-based approach to drug discovery, founded on its industry-leading expertise in network biology to fully capture disease complexity. The Company combines network science, machine learning, artificial intelligence, statistics, and big data with expertise in drug discovery and development to transform the search for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that enables the rapid screening of millions of compounds and the identification of small sub-sets that are enriched for highly active hits. Its proprietary platform also has novel applications in functional genomics, being able to analyze complex genetic datasets, provide a deep understanding of pathological mechanisms and distill actionable insights for the discovery of novel drugs, biomarkers, and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic drug discovery platform both in-house and with partners, including Novo Nordisk, Galapagos NV, and a US-based, top 5 pharmaceutical company.
For more information: https://www.etherapeutics.co.uk/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
